IgG的Fc段的免疫耐受特性及其在血友病治疗与管理中的意义
血友病是凝血因子遗传性缺乏导致的出血性疾病,需预防性或按需重组蛋白替代治疗,但患者可能对输注蛋白产生免疫反应。重组凝血因子Ⅷ和Ⅸ与IgG的Fc段融合可延长半衰期,Fc段还具有诱导免疫耐受的免疫调节特性。本文综述了IgG Fc免疫耐受能力的最新进展及Fc融合rFVIII对血友病治疗的影响。
要点
- 血友病需重组凝血因子替代治疗,但存在产生免疫反应的风险。
- rFVIII和rFIX与IgG Fc段融合已分别开发为血友病A和B的治疗药物。
- IgG Fc段不仅延长半衰期,还具有诱导免疫耐受的免疫调节特性。
核心结论
- IgG Fc段具有诱导免疫耐受的特性,Fc融合rFVIII对血友病治疗具有影响。
研究设计与样本
- 综述,总结IgG Fc免疫耐受能力的最新进展及Fc融合rFVIII对血友病治疗的影响。
主要发现
- rFVIII和rFIX分别与IgG Fc段融合,已开发为血友病A和B的治疗药物。
- IgG Fc段除延长循环半衰期外,还具有诱导免疫耐受的免疫调节特性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophilia, or inherited genetic deficiencies in coagulation factors, results in uncontrolled bleeding requiring replacement therapy with recombinant proteins given preventively or on demand. However, a major problem with these approaches is the potential for development of immune responses to the administered proteins due to the underlying genetic deficiency of the factor(s) throughout life. As such, there is great interest in developing strategies that avoid immunogenicity and induce immune tolerance. Recently, recombinant factor VIII (rFVIII) and rFIX fused to the crystallizable fragment (Fc) domain of immunoglobulin G (IgG) have been developed as therapeutic agents for hemophilia A and B, respectively. Although it is well known that the possession of an Fc domain confers IgG's longer-lasting circulating half-life, it is not generally appreciated that the Fc domain also confers immunoregulatory properties that are associated with the induction of tolerance. Here, we review some of the latest advances in our understanding of the tolerogenic abilities of IgG Fc and the impact of Fc-fusion proteins of rFVIII on the treatment of hemophilia.
引用
- Blumberg RS, Lillicrap D. Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia. Blood. 2018. PMID: 29588277. doi:10.1182/blood-2017-12-822908
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。